NZ712935A - Methods for treatment of nephrotic syndrome and related conditions - Google Patents

Methods for treatment of nephrotic syndrome and related conditions

Info

Publication number
NZ712935A
NZ712935A NZ712935A NZ71293514A NZ712935A NZ 712935 A NZ712935 A NZ 712935A NZ 712935 A NZ712935 A NZ 712935A NZ 71293514 A NZ71293514 A NZ 71293514A NZ 712935 A NZ712935 A NZ 712935A
Authority
NZ
New Zealand
Prior art keywords
nephrotic syndrome
methods
treatment
disease
present disclosure
Prior art date
Application number
NZ712935A
Other languages
English (en)
Inventor
Sumant S Chugh
Original Assignee
Sumant S Chugh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,240 external-priority patent/US9139629B2/en
Application filed by Sumant S Chugh filed Critical Sumant S Chugh
Publication of NZ712935A publication Critical patent/NZ712935A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ712935A 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions NZ712935A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/841,240 US9139629B2 (en) 2010-06-05 2013-03-15 Methods for treatment of nephrotic syndrome and related conditions
PCT/US2014/030009 WO2014145275A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Publications (1)

Publication Number Publication Date
NZ712935A true NZ712935A (en) 2020-03-27

Family

ID=51537930

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712935A NZ712935A (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Country Status (8)

Country Link
EP (1) EP2970416B1 (https=)
JP (1) JP2016516726A (https=)
KR (1) KR102221041B1 (https=)
CN (1) CN105229024A (https=)
AU (1) AU2014233219B2 (https=)
CA (3) CA2906982C (https=)
NZ (1) NZ712935A (https=)
WO (1) WO2014145275A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706296B1 (ko) 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
US20180201645A1 (en) * 2015-12-21 2018-07-19 Brainon Inc. Composition for improving memory, learning ability, and cognitive ability
EP3803412A1 (en) 2018-06-01 2021-04-14 Laboratory Corporation of America Holdings Simplified biosample processing for lc-ms/ms
CN112292125B (zh) * 2018-06-22 2023-10-31 西奈克制药有限公司 蛋白尿的治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1781698T (lt) * 2004-07-20 2016-09-26 Genentech, Inc. Į angiopoetiną panašaus baltymo 4 kompozicijos ir panaudojimo būdai
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
EP3318269B1 (en) * 2010-06-05 2024-03-13 Chugh, Sumant S. Use of an angiopoietin-like 4 (angptl4) polypeptide in the manufacture of a medicament for the treatment of proteinuria.
US20110301103A1 (en) * 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment

Also Published As

Publication number Publication date
KR20150140686A (ko) 2015-12-16
CA3152699C (en) 2023-09-05
CA2906982A1 (en) 2014-09-18
EP2970416A1 (en) 2016-01-20
WO2014145275A1 (en) 2014-09-18
CA3207108A1 (en) 2014-09-18
CN105229024A (zh) 2016-01-06
AU2014233219B2 (en) 2018-02-22
HK1220213A1 (en) 2017-04-28
AU2014233219A1 (en) 2015-10-08
KR102221041B1 (ko) 2021-02-25
CA3152699A1 (en) 2014-09-18
JP2016516726A (ja) 2016-06-09
EP2970416B1 (en) 2023-11-22
EP2970416A4 (en) 2017-02-22
EP2970416C0 (en) 2023-11-22
CA2906982C (en) 2022-05-31

Similar Documents

Publication Publication Date Title
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
HK1213483A1 (zh) Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
JO3472B1 (ar) مركبات ديهايدروبنزوفوران مفيدة في علاج السكري والسمنة
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
PH12016501614A1 (en) Heterocyclic compound
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
HK1226084A1 (zh) 用於治疗糖尿病的gip和glp-1受体双重激动剂
UA118558C2 (uk) Пептидна сполука
WO2014091316A3 (en) Glucagon/glp-1 agonists for the treatment of obesity
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
PH12014501336A1 (en) Glucagon analogues
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
MX356000B (es) Analogos de glucagon que exhiben actividad del receptor gip.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EP4306174A3 (en) Composition for controlled ovarian stimulation
MX2021008663A (es) Anticuerpos mejorados contra il-6.
MX366636B (es) Nuevo derivado de un análogo de insulina.
NZ712935A (en) Methods for treatment of nephrotic syndrome and related conditions
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX2017000087A (es) Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.
HK1221666A1 (zh) 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法
HK1214520B (en) Treatment of diabetes mellitus by long acting formulations of insulins
MA43070A (fr) Composition herbicide à base de cinméthyline et de pyroxasulfone
UA107743C2 (ru) Способ лечения аденокарциномы

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SUMANT S CHUGH, US

Effective date: 20160908

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2022 BY AJ PARK

Effective date: 20210524

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2023 BY AJ PARK

Effective date: 20220324

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2024 BY AJ PARK

Effective date: 20230224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2025 BY PATRIX IP SERVICES AB

Effective date: 20240212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2026 BY PATRIX IP SERVICES AB

Effective date: 20250215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2027 BY PATRIX IP SERVICES AB

Effective date: 20260211